Form 4: Adaptive Biotechnologies CFO Executes Sell-to-Cover Trade

CFO Kyle Piskel sold 3,115 shares of Adaptive Biotechnologies to satisfy tax obligations related to RSU vesting.

Summary

• Kyle Piskel, Chief Financial Officer of Adaptive Biotechnologies Corporation, sold 3,115 shares of common stock.
• The transaction occurred on May 18, 2026, at a price of $13.04 per share.
• Following the transaction, the reporting person retains beneficial ownership of 256,725 shares.
• The sale was a mandatory 'sell-to-cover' transaction to satisfy tax withholding obligations associated with the vesting of restricted stock units (RSUs).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was a mandatory administrative action rather than a discretionary market move.

Positives

• The transaction was non-discretionary and mandated by the company's equity incentive plan requirements.

Negatives

• Reduction in the direct share ownership of a key executive.

Risks

• None identified; this is a routine administrative transaction.

Future Outlook

No forward-looking guidance provided in this filing.

Management Comments

• The transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs.

Industry Context

StockSavvy.ai notes that 'sell-to-cover' transactions are standard industry practice for executives receiving equity-based compensation and do not typically signal a change in management sentiment regarding company performance.

Comparison to Industry Standards

• The transaction aligns with standard corporate governance practices for handling tax obligations on vested equity awards.

Stakeholder Impact

• Minimal impact on shareholders as the sale was non-discretionary and limited in volume.

Next Steps

• None

Key Dates

Keywords

Adaptive Biotechnologies, ADPT, Insider Trading, Form 4, CFO, Equity Compensation